TONIX PHARMACEUTICALS

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.
TONIX PHARMACEUTICALS
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2007-11-16
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.tonixpharma.com
Total Employee:
11+
Status:
Active
Contact:
212-980-9155
Total Funding:
257.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Font Awesome
Current Advisors List
Board_member
2010-11-01
Current Employees Featured
Bradley Saenger Chief Financial Officer and Treasurer @ Tonix Pharmaceuticals
Chief Financial Officer and Treasurer
Seth Lederman Co-Founder, CEO, and Chairman @ Tonix Pharmaceuticals
Co-Founder, CEO, and Chairman
Gregory Sullivan Chief Medical Officer @ Tonix Pharmaceuticals
Chief Medical Officer
Bruce L. Daugherty Senior Director of Drug Development @ Tonix Pharmaceuticals
Senior Director of Drug Development
Jeffrey Rosenfeld Executive Director, Genomics and Bioinformatics @ Tonix Pharmaceuticals
Executive Director, Genomics and Bioinformatics
2022-03-01
Jessica Morris COO @ Tonix Pharmaceuticals
COO
Leland Gershell Chief Financial Officer and Treasurer @ Tonix Pharmaceuticals
Chief Financial Officer and Treasurer
Founder
Stock Details
Investors List
Broadfin Capital
Broadfin Capital investment in Post-IPO Equity - Tonix Pharmaceuticals
Sabby Management
Sabby Management investment in Post-IPO Equity - Tonix Pharmaceuticals
Deerfield
Deerfield investment in Post-IPO Equity - Tonix Pharmaceuticals
Technology Partners
Technology Partners investment in Post-IPO Equity - Tonix Pharmaceuticals
Key Employee Changes
Date | New article |
---|---|
2022-03-09 | Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics |
Official Site Inspections
http://www.tonixpharma.com Semrush global rank: 1.74 M Semrush visits lastest month: 13.64 K
- Host name: gra.graphicainc.com
- IP address: 162.241.142.33
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606

More informations about "Tonix Pharmaceuticals"
About - Tonix Pharmaceuticals
Our Mission, Vision, and Core Values Our Mission is to improve population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities …See details»
Tonix Pharmaceuticals - Wikipedia
Tonix Pharmaceuticals Holding Corp. (TNXP)
4 days ago Company. Tonix Pharmaceuticals Holding Corp. 26 Main Street Suite 101 Chatham, NJ 07928 T: 862-799-8599See details»
Clinical Trials - Tonix Pharmaceuticals
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, …See details»
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense ...
Mar 10, 2025 The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related …See details»
Tonix Pharmaceuticals - LinkedIn
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent ...See details»
TONIX PHARMACEUTICALS HOLDING CORP.
Contact Email jobs@tonixpharma.com Phone Number (862)-799-9155 Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent …See details»
News & Events - Tonix Pharmaceuticals Holding Corp.
Aug 16, 2024 World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1. ... This press release …See details»
Working At Tonix Pharmaceuticals: Company Overview and …
Www.tonixpharma.com. Organization Type. Public. Social Media. Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the development …See details»
Tonix Pharmaceuticals - Craft
Oct 29, 2024 Tonix Pharmaceuticals has 5 employees across 6 locations and $10.09 m in annual revenue in FY 2024. See insights on Tonix Pharmaceuticals including office locations, …See details»
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense ...
Mar 10, 2025 The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related …See details»
Tonix Pharmaceuticals - Facebook
Ir.tonixpharma.com. Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences. Tonix Pharmaceuticals to Present at Two Upcoming January Investor …See details»
Therapeutic Areas Overview - Tonix Pharmaceuticals
Therapeutic Areas Tonix Pharmaceuticals is dedicated to advancing the science to improve patient care and public health.We are developing novel treatments across a range of …See details»
Tonix Pharmaceuticals Announces Grant by Medical CBRN
Mar 10, 2025 This press release and further information about Tonix can be found at www.tonixpharma.com. 1 Noyce RS, et al. Viruses. 2023 Jan 26;15(2):356. Doi: …See details»
Tonix Pharmaceuticals Announces Transition to Fully Integrated ...
Mar 19, 2024 Since the acquisition of Zembrace ® SymTouch ® (sumatriptan injection) 3 mg and Tosymra ® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals …See details»
Tonix Pharmaceuticals Announces Transition to Fully Integrated ...
Mar 19, 2024 Since the acquisition of Zembrace ® SymTouch ® (sumatriptan injection) 3 mg and Tosymra ® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals …See details»
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor …
Mar 5, 2025 Jessica Morris Tonix Pharmaceuticals investor.relations@tonixpharma.com (862) 799-8599. Peter Vozzo ICR Healthcare peter.vozzo@icrhealthcare.com (443) 213-0505. …See details»
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 ...
Mar 18, 2025 In September 2024, the Company announced that the World Health Organization’s (WHO) preferred target product profile ... You can also visit https://www.tonixpharma.com or …See details»
Tonix Pharmaceuticals Announces Expansion of Leadership Team …
Dec 3, 2024 This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements. Certain statements in this press release …See details»
Tonix Pharmaceuticals Announces Presentation at the American …
1 day ago CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with …See details»